This document provides an overview of bronchial asthma, including its definition, types, pathophysiology, treatment approaches, and recent advances. Bronchial asthma is a chronic inflammatory disease of the airways characterized by reversible bronchial hyperresponsiveness and airflow limitation caused by bronchoconstriction and inflammation. It is classified based on etiology such as allergic or exercise-induced asthma, and symptoms from intermittent to severe. Treatment involves both controllers like corticosteroids and long-acting bronchodilators for long-term control, and relievers like short-acting bronchodilators for acute symptoms. Recent advances include monoclonal antibodies targeting IgE and IL-5, bronchial thermoplasty, and subcutaneous immunotherapy

1. SMS Medical College, Jaipur
Management of Bronchial Asthma
Dr. Jaya Dadhich
Resident,
Department of Pharmacology

2. Learning Objectives
• What is Bronchial asthma
• Types of asthma
• Brief understanding about pathophysiology
• Classification of Drugs for it
• Treatment approach
• Recent advances in treatment
• Summary

3. What is Bronchial asthma ?
Reversible chronic bronchial hyper-
responsiveness of the airways to various
stimuli,
• bronchoconstriction,
• airflow limitation and
• inflammation of the bronchi
causing symptoms of cough, wheeze, chest
tightness and dyspnoea.

4. Types of asthma
According to etiology
• Allergic asthma
• Exercise induced asthma
• Steroid resistant asthma
• Intrinsic asthma
• Occupational
• Brittle asthma
According to symptoms
• Intermittent
• Mild
• Moderate
• Moderately Severe
• Severe

5. Pathophysiology of Bronchial Asthma

6. Treatment
Controllers
• Long-acting medications to
achieve and maintain control
of persistent asthma
• Corticosteroids
• Mast cell stabilizers
• Long- acting beta2-adrenergic
agents
• XANTHINE derivatives
• LEUKOTRIENE MODIFIERS
(inhibitors)
• Combination products .
Relievers
• Quick- relief medications for
immediate treatment of
asthma symptoms and
exacerbations
• Short-acting beta-
adrenergic agonists.
• Anticholinergics (eg,
ipratropium bromide)

9. Recent advances
• MABs against IgE Omalizumab
• PDE-4 inhibitors
Roflumilast
Cilomilast
Tofimilast
• MABs Against IL-5
Mepolizumab
Reslizumab
• Bronchial thermoplasty
• SCIT (subcutaneous immunotherapy)

10. Conclusion
• Asthma is common and can start at any age but it
can be effectively controlled.
• Effective asthma management includes patient
education, objective measurement of lung
function, environmental control, and
pharmacologic therapy
• A stepwise approach to pharmacologic therapy is
recommended
• The aim is to accomplish the goals of therapy
with the least possible medication.

11. References
1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al.
International ERS/ATS guidelines on definition, evaluation and
treatment of severe asthma. European Respiratory Journal. 2014;
43(2):343–373 [PubMed]
2. Donald KJ, McBurney H, Teichtahl H, Irving L. A pilot study of
telephone based asthma management. Australian Family
Physician. 2008; 37(3):170–173 [PubMed]
3. Halvani A, Tahghighi F, Nadooshan HH. Evaluation of correlation
between airway and serum inflammatory markers in asthmatic
patients. Lung India. 2012; 29(2):143–146 [PMC free article]
[PubMed]
4. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of
life in asthma. American Review of Respiratory Disease. 1993;
147(4):832–838 [PubMed]

12. Thank you